Business Context and Reporting Period
The filing is a Form 6-K for China Jo-Jo Drugstores, Inc., not Ridgetech Inc.; the source metadata and filing issuer do not match. The unaudited financial statements cover the six months ended September 30, 2023, with balance-sheet comparisons to March 31, 2023 and operating/cash-flow comparisons to September 30, 2022.
The company operates 128 pharmacies in Hangzhou and has online pharmacy, wholesale, and farming segments. No farming revenue was reported. The company stated that COVID-19 currently has no significant impact on operations.
Key Financial Metrics
| Metric | Six months ended September 30, 2023 | Comparable period / prior balance |
|---|---|---|
| Revenue | $78.6 million | $72.7 million; up 8.0% |
| Gross profit | $15.9 million | $16.9 million; down 5.8% |
| Gross margin | 20.3% | 23.3% |
| Operating income (loss) | $0.3 million | $(1.2) million |
| Operating margin | 0.3% | (1.7)% |
| Net loss | $(0.9) million | $(0.6) million |
| Net loss attributable to the company | $(0.9) million | $(0.6) million |
| Operating cash flow | $0.7 million | $1.1 million |
| Investing cash flow | $(1.3) million | $(0.1) million |
| Financing cash flow | $0.3 million | $(3.0) million |
| Cash and restricted cash | $29.6 million | $31.6 million at period start |
| Working capital | $36,906 | Based on current assets of $69.8 million and current liabilities of $69.8 million |
At September 30, 2023, total assets were $94.8 million, total liabilities were $77.2 million, and shareholders’ equity was $17.5 million. Notes payable were $24.5 million, while operating lease liabilities totaled $12.5 million, including current and long-term portions.
Material Changes Versus Prior Comparable Period
- Revenue increased $5.9 million, primarily from wholesale growth of $10.6 million, or 69.0%, and online sales growth of $1.9 million, or 13.2%.
- Retail drugstore revenue decreased $6.6 million, or 15.3%, to $36.6 million. Management attributed the decline primarily to weaker local consumption and reduced demand for medical products.
- Gross profit declined despite higher revenue, and gross margin fell three percentage points to 20.3%, reflecting lower retail and wholesale profitability.
- Operating results improved to income of $0.3 million from an operating loss of $1.2 million, aided by lower selling expenses and a 55.1% reduction in general and administrative expenses.
- Net loss increased to $0.9 million, primarily because of a $1.6 million investment loss related to Zhejiang Zhuoli Life Service Co., Ltd. and lower other income.
- Operating cash flow declined to $0.7 million from $1.1 million. Investing outflows increased mainly because of a $1.1 million investment in a joint venture.
- Accounts payable increased to $34.4 million from $27.0 million, while inventories increased to $19.6 million from $15.3 million.
Outlook, Commentary, Risks, and Unusual Items
- Management expects retail sales to recover and continue growing, supported by local community sales events and membership programs; no quantified guidance was provided.
- Online pharmacy competition remains intense, particularly from large platforms such as TikTok and other well-funded competitors using discounts and promotional subsidies.
- Retail margins may be pressured by reductions in prices reimbursed by local health insurance agencies and limited supplier pricing flexibility.
- Wholesale margins remain low and variable because the company lacks significant bargaining power and has not made substantial progress obtaining exclusive products or access to major hospitals.
- The $1.6 million investment loss relates to operating and expansion expenses incurred by Zhuoli Service; the filing does not provide a clear valuation or recovery outlook for the investment.
- Liquidity is tight: current assets and current liabilities were nearly equal, producing only $36,906 of working capital. Cash declined during the period, although operating activities generated positive cash flow.
- The company identifies forward-looking statement risks by reference to the risk factors in its Form 20-F for the year ended March 31, 2023. The filing text does not provide additional quantified contingency or covenant information.
- On March 1, 2024, the company completed a 1-for-20 reverse stock split. Historical share and per-share data were retroactively restated.
Investor Verification Items
- Verify the issuer identity, because the filing names China Jo-Jo Drugstores, Inc. while the request identifies Ridgetech Inc.
- Reconcile the near-zero working capital position with upcoming notes payable, lease obligations, supplier payables, and required operating liquidity.
- Assess the sustainability of revenue growth given the sharp decline in retail sales and the increasing contribution from lower-margin wholesale activity.
- Review the valuation, ownership, financial condition, and recoverability of the Zhuoli Service investment that generated the $1.6 million loss.
- Confirm the effects of the March 2024 reverse stock split on current share count, trading price, dilution, and per-share amounts.
- Review the company’s Form 20-F risk factors, debt terms, related-party balances, and any commitments or contingencies not detailed in this interim filing.